Study of INV-102 Ophthalmic Solution in Adults With Moderate Symptomatic Dry Eye Disease
Completed · Phase 1/Phase 2
Conditions studied: Dry Eye Disease
In brief
Phase 1/2, first-in-human, 2-part study to assess topically administered eyedrops of INV-102 during 2-week repeat dosing in subjects with moderate symptomatic dry eye disease. Part 1 will be a Dose Escalation phase across 4 cohorts of subjects to assess safety and tolerability of INV-102, and Part 2 will be an Optional Dose Expansion phase in a fifth cohort of subjects, pending the outcome of Part 1, to assess efficacy of INV-102 in the treatment of moderate symptomatic dry eye disease.
Key facts
- Study ID
- NCT05586152
- Run by
- Invirsa, Inc.
- People needed
- 84
- Starts
- 2022-08-30
- Expected to finish
- 2023-05-02
- Last updated by the study team
- 2026-04-27
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: not accepted.
Where it is running
- iuvo BioScience — Rush, New York, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.